About ADAPTABLE

The purpose of ADAPTABLE is to find the best dose of aspirin, 81 mg or 325 mg, for people with known or existing heart disease to prevent death or another heart attack or stroke.

What did we learn?

With your valuable contribution, we successfully completed a virtual trial with 15,076 participants.

There were no differences in rates of death, hospitalization for a heart attack or stroke, and bleeding between participants who took 81 mg and those who took 325 mg.

Over the course of the trial, participants who were assigned to 325 mg of aspirin were more likely to switch doses or stop taking aspirin than people assigned to 81 mg.

This dose switching and discontinuation may have impacted the results. Reasons for switching or stopping aspirin during the study may have been due to issues tolerating aspirin, health problems, and patient or clinician preference.

How will the results help people with heart disease and those who care for them?

People with heart disease should discuss the following aspirin dosing guidelines with their clinicians:

If you are on 81 mg now, staying (rather than switching to 325 mg) is probably right since no differences were found between the two doses.

If you are resuming aspirin, starting a lower dose (81 mg) is probably right due to better tolerability and there is no conclusive evidence that a higher dose is better.

If you are on 325 mg now and doing okay, staying on it may be fine.